Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy.
about
Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitorRSK in tumorigenesis: connections to steroid signaling.Effect of estrogen receptor β agonists on proliferation and gene expression of ovarian cancer cellsPrognostic value of progesterone receptor expression in ovarian cancer: a meta-analysisRetinoids and ovarian cancer.Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer.GPR30 predicts poor survival for ovarian cancerEpidermal growth factor receptor is a critical mediator of ultraviolet B irradiation-induced signal transduction in immortalized human keratinocyte HaCaT cells.Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: implications for personalized cancer therapy.The G protein-coupled estrogen receptor 1 (GPER/GPR30) does not predict survival in patients with ovarian cancer.Immunoradiometric and immunohistochemical analysis of Cathepsin D in ovarian cancer: lack of association with clinical outcomePrognostic significance of ras/p21 alterations in human ovarian cancer.p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer.Lack of relationship between EGFR-1 immunohistochemical expression and prognosis in a multicentre clinical trial of 93 patients with advanced primary ovarian epithelial cancer (GINECO group)Hormone response in ovarian cancer: time to reconsider as a clinical target?Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysisPredictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies.EGFR(s) in aging and carcinogenesis of the gastrointestinal tract.Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies.Establishment of a human non-small cell lung cancer cell line resistant to gefitinib.Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo.Correlation between estrogen receptor expression and prognosis in epithelial ovarian cancer: a meta-analysis.Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression.Estradiol attenuates EGF-induced rapid uPAR mobilization and cell migration via the G-protein-coupled receptor 30 in ovarian cancer cells.Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer.Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13).Loss of estrogen receptor beta isoform expression and its correlation with aberrant DNA methylation of the 5'-untranslated region in human epithelial ovarian carcinoma.Hormone-receptor expression status of epithelial ovarian cancer in Ibadan, South-western Nigeria.Interrelationships between cellular nucleotide excision repair, cisplatin cytotoxicity, HER-2/neu gene expression, and epidermal growth factor receptor level in non-small cell lung cancer cells.
P2860
Q28368986-C067F407-CF10-4D7F-B0C3-27E69F04DB2EQ30433106-AABEFDB6-89AD-4B06-B9D3-A5BD15B02AE3Q33651509-C1FF5CB8-7712-4531-8704-17BAAFE3786AQ33829679-71DBF956-5B86-4F74-BDBD-352F2B656DD2Q34002981-F661235A-1473-4F60-A236-1BFC0AC9E66CQ34022694-2542A7A1-7E44-42E2-972B-E99BC03B30B4Q34066297-9390BB09-5A0E-4454-894A-CD3F75F385E6Q35222011-CEEFDEB7-B298-4B71-9856-0157F6C631A8Q35328194-E717739C-E7EF-44E0-8CB4-38307CCA617CQ35946017-3E8776D5-7997-48A6-9D95-A7E6E4DF285AQ36115828-A86F561F-5D36-4F66-A524-DCB405AFC622Q36421674-0D3E7269-26BC-43E2-83AF-D4B251B55FB8Q36619706-9AC6A3AB-A5D7-4E28-A033-8FBC6323D30FQ36695522-563B0DD4-85B9-42F4-83E1-9740E6AD6A10Q36966197-39FC015B-22C6-45EF-B6E6-6981C2785A3CQ37269642-65BEC240-9A4B-4E7F-9AEB-11957FCF687CQ37328373-956626EB-95D5-41B4-9C75-59217D4D20ABQ37552436-980520F0-8689-493D-A241-6BF2624C5ECAQ38099749-321C6B74-0526-4681-BEC2-21377130AE43Q40447861-E4391442-808D-499A-B100-7D44CF93E0E9Q40749244-3E78D31F-3F69-4CE9-A9D1-A279CB1A73FFQ42365343-FD7C6D95-05D0-4305-8B66-35695A3A20DDQ42803600-F3F22EA4-E238-48BE-AAAF-436D481C8B25Q43636529-F5FF8CCD-4BF5-41B8-988D-823CAC6C6481Q44068928-842DFD74-8A9B-452C-9874-E521A51BE178Q44324783-6C4C0F1E-E7CE-4007-8D35-FDBABDC3C2B7Q46229672-BC352F31-FE41-4D25-99D6-22C4F2F99DB2Q46747718-E372DF21-8AFE-4C3E-8E8D-E7C4C495FC17Q55001941-3A04FCA8-D18C-4304-93F7-D31CD90162CA
P2860
Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Epidermal growth factor, oestr ...... and response to chemotherapy.
@ast
Epidermal growth factor, oestr ...... and response to chemotherapy.
@en
type
label
Epidermal growth factor, oestr ...... and response to chemotherapy.
@ast
Epidermal growth factor, oestr ...... and response to chemotherapy.
@en
prefLabel
Epidermal growth factor, oestr ...... and response to chemotherapy.
@ast
Epidermal growth factor, oestr ...... and response to chemotherapy.
@en
P2093
P2860
P356
P1476
Epidermal growth factor, oestr ...... e and response to chemotherapy
@en
P2093
M Distefano
M E Romanini
P Benedetti-Panici
P2860
P2888
P304
P356
10.1038/BJC.1995.339
P407
P50
P577
1995-08-01T00:00:00Z